stockrowLexicon Pharmaceuticals, Inc. (LXRX) vs Rigel Pharmaceuticals, Inc. (RIGL)
- Lexicon Pharmaceuticals, Inc. LXRX 1.86 −0.53%
- Rigel Pharmaceuticals, Inc. RIGL 44.95 +0.97%
Lexicon Pharmaceuticals, Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Lexicon Pharmaceuticals, Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($838.3M and $832.6M). Lexicon Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 2.18% against −45.6%. Rigel Pharmaceuticals, Inc. has the higher net margin (106.6% vs −161.8%) and the higher return on invested capital (13.7% vs −109.1%). Across the 18 metrics below, Rigel Pharmaceuticals, Inc. leads on 16 and Lexicon Pharmaceuticals, Inc. on 2.
Valuation
Profitability
| Metric | LXRX | RIGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 98.89% | 89.64% | 68.81% |
| Operating margin | (147.42%) | 26.28% | 0.00% |
| Net margin | (161.80%) | 106.59% | 0.00% |
| Free cash flow margin | (127.76%) | 6.72% | 0.00% |
| Return on equity | (43.91%) | 109.18% | (50.30%) |
| Return on assets | (27.84%) | 80.16% | (45.47%) |
| Return on invested capital | (109.13%) | 13.69% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack